Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:139715437" >
Pharmacogenetic imp...
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients
-
Sim, S (författare)
-
- Bergh, J (författare)
- Karolinska Institutet
-
Hellstrom, M (författare)
-
visa fler...
-
- Hatschek, T (författare)
- Karolinska Institutet
-
- Xie, HJ (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Future Medicine Ltd, 2018
- 2018
- Engelska.
-
Ingår i: Pharmacogenomics. - : Future Medicine Ltd. - 1744-8042 .- 1462-2416. ; 19:16, s. 1259-1268
- Relaterad länk:
-
http://kipublication...
-
visa fler...
-
https://doi.org/10.2...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aim: This study aimed to investigate the effect of CYP3A4 and CYP3A5 genotypes on clinical outcomes of docetaxel treatment. Patients & methods: In the PROMIX trial, 150 breast cancer patients received docetaxel preoperatively. CYP3A4 and CYP3A5 genotype combinations were transformed into total CYP 3A phenotypes. Results: Seven patients were characterized as poor metabolizer (PM), 22 patients as extensive metabolizer and 121 patients as intermediate metabolizer. The frequency of grade 3/grade 4 adverse events was higher in the PM group (p = 0.002). One PM subject who basically lacked enzyme activity died from typhlitis. Total 45 recurrences were reported after a median of 5-year follow-up; none of these was PM. Conclusion: The allelic variants CYP3A4*22 and CYP3A5*3 contribute to the interpatient variations of docetaxel.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas